AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04847518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kan Jang capsules
Description: One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate).
Study NCT04847518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Inactive excipients
Study NCT06435689 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: Blood and surgical specimen sampling the day of surgery
Study NCT05719012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: UC-MSCs
Description: Intravenous injection three times with one-month interval
Study NCT03098225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy
Description: A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
Study NCT03098225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
Study NCT03098225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
Study NCT05719012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Intravenous injection three times with one-month interval
Study NCT06485063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Reorganization
Description: It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
Study NCT06485063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO Myofascial Reorganization
Description: it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
Study NCT04216927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
Study NCT04216927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen alone will be entrained for placebo arm
Study NCT05465265 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)
Description: Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
Study NCT05465265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)
Description: Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
Study NCT04991571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan (Treatment A)
Description: Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
Study NCT04991571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (Treatment A)
Description: Dapagliflozin tablet will be administered orally as single dose in Part 2.
Study NCT04991571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
Description: Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
Study NCT04991571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Description: Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
Study NCT05692245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Administered Medication
Study NCT05692245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administered Medication
Study NCT06204107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379(Empagliflozin+sitagliptin+metformin) Test drug
Description: oral, once
Study NCT06204107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
Description: oral, once
Study NCT04778475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Description: PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
Study NCT04778475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: PT services 3-5 times a week for 15 to 30 minutes
Study NCT05966948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose Solution
Description: Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
Study NCT05966948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
Study NCT05049265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS007
Description: JS007 only
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Black Girl)
Description: A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Black Boy)
Description: A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Latinx Girl)
Description: A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Latinx Boy)
Description: A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (White Girl)
Description: A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (White Boy)
Description: A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Nonbinary or transgender)
Description: A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
Study NCT06222528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A video that will provide information about depression and how to seek help but does not include a personal story.
Study NCT05852860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text.
Study NCT05852860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
Study NCT05582174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
Study NCT05582174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
Study NCT06238804 — intervention group
Intervention type: PROCEDURE
Intervention: KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches
Description: A3.1, A3.2, A3.3
Study NCT06464263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
Study NCT06201286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept
Description: Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
Study NCT06201286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching and strengthening exercises
Description: Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
Study NCT05928052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Biopac Electrical Stimulator
Description: A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
Study NCT06208995 — intervention group
Intervention type: OTHER
Intervention: 36-Item Short Form Survey Instrument (SF-36)
Description: Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html
Study NCT05755984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: scan
Study NCT05284838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error Management Training (Difficult)
Description: Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
Study NCT05284838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error Management Training (Easy)
Description: Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
Study NCT05284838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Error Avoidance Training
Description: Error Avoidance Training used to teach head computed tomography interpretation.
Study NCT05963997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: Samuraciclib capsules by mouth once a day
Study NCT04646499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
Study NCT05963997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant Dihydrochloride
Description: Elacestrant tablets by mouth once a day
Study NCT04985669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride 2mg
Description: one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
Study NCT04985669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride 2mg
Description: one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05516082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: DDH contact lens for 15 minutes
Study NCT05516082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: DDSH contact lens for 15 minutes
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g tid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g tid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid
Study NCT05014685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1g tid
Study NCT05165212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
Study NCT05834517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
Study NCT05396196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: Manual Fascial Glide Application
Study NCT05396196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio® Tape
Description: Manual Fascial Glide Application
Study NCT05834517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non surgical periodontal therapy
Description: NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
Study NCT05584553 — intervention group
Intervention type: DEVICE
Intervention: ToggleLoc 2.9 mm soft tissue device
Description: The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
Study NCT05584553 — intervention group
Intervention type: DEVICE
Intervention: JuggerLoc soft tissue device
Description: The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
Study NCT06208111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
Study NCT05515991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT-DIALYSIS with Access to Output Report and Information Hub
Description: SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals.
Study NCT05515991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT-DIALYSIS Only
Description: SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
Study NCT06514313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
Description: Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
Study NCT06514313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide+Irinotecan+Vincristine
Description: Q3W, 4 cycles
Study NCT05604742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab (Benlysta)
Description: Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
Study NCT06479577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
Study NCT06479577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity laser therapy
Description: 905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
Study NCT05816434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: >1 hour additional time in bed per night for 1 week.